Ar
Non verificato

Arcturus Therapeutics Holdings Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaHIV, AIDS e malattie autoimmuniMedicina - VarieSalute
24/11/2025
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Eventi
Arcturus Therapeutics to Attend Upcoming Investor Conference
1.00
10/11/2025
Web e Social Network
Telefonia e Varie
Mercato azionario
Salute
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Farmaceutica
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress
1.00
04/11/2025
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Eventi
Arcturus Therapeutics to Attend Upcoming Investor Conferences
1.00
28/10/2025
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025
1.00
22/10/2025
Biotecnologia
Igiene alimentare
Salute
Sanità
Farmaceutica
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Industria
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
1.00
26/08/2025
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Eventi
Arcturus Therapeutics to Attend Upcoming Investor Conferences
1.00
11/08/2025
Salute
HIV, AIDS e malattie autoimmuni
Biotecnologia
Sanità
Farmaceutica
Web e Social Network
Telefonia e Varie
Mercato azionario
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress
1.00
24/07/2025
Salute
HIV, AIDS e malattie autoimmuni
Biotecnologia
Sanità
Farmaceutica
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
1.00
23/07/2025
HIV, AIDS e malattie autoimmuni
Biotecnologia
Farmaceutica
Salute
Eventi
Arcturus Therapeutics to Attend Upcoming Investor Conferences
1.00
30/06/2025
HIV, AIDS e malattie autoimmuni
Biotecnologia
Farmaceutica
Salute
Eventi
Industria
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0